Pharmacokinetics and Elimination Efficiency of Linezolid during Dialysis. (April 2013)

• Record Type: Journal Article
• Authors: Hiraki, Yoichi; Tsuji, Yasuhiro; Misumi, Nobuhiro; Hiraike, Mikako; Matsumoto, Kana; Morita, Kunihiko; Kamimura, Hidetoshi; Karube, Yoshiharu
• Is Part Of: Renal failure. Volume 35:Number 3(2013)
• Page Start: 418
• Page End: 420
• Publication Date: 2013-04
• Subjects: Chronic renal failure -- Periodicals; Acute renal failure -- Periodicals; Uremia -- Periodicals; 616.614005
• DOI: 10.3109/0886022X.2012.761085
• Languages: English
• ISSNs: 0886-022X

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Linezolid (LZD) is an option for treating infections caused by multi-resistant Gram-positive bacteria. The protein-binding rate of LZD markedly influences its elimination by dialysis, with limited data suggesting that LZD is cleared by intermittent hemodialysis. Here, we investigated the protein-binding rate and elimination efficiency of LZD in a sepsis patient receiving dialysis. The oral administration of LZD at 600 mg/day resulted in protein-binding and free rates of the drug of 20.4% and 79.6%, respectively, 24 h after administration. By comparing the LZD concentration before and after dialysis, the elimination efficiency of free LZD as a result of dialysis was found to be 40.6%. Our sepsis patient showed higher plasma concentrations of LZD at trough after hemodialysis than the reported concentrations in normal renal function patients. However, it is not clear from our present findings if a relationship exists between myelosuppression and plasma LZD concentration.</p> </abstract>